Европейски съюз - български - EMA (European Medicines Agency)

janssen-cilag international nv - esketamine хидрохлорид - Депресивно Разстройство - Други антидепресанти - spravato, в съчетание с ssri или СИОЗН, предназначени за възрастни с резистентной към терапията на депресивните разстройства, които не са отговорили на поне две различни техники за лечение с антидепресанти в днешно умерени и тежки депресивни епизода.

Европейски съюз - български - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - Хеморагична Треска Ебола - Ваксини - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Европейски съюз - български - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - Хеморагична Треска Ебола - Ваксини - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Европейски съюз - български - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - Ваксини - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.

Европейски съюз - български - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - Карцином, недребноклетъчен белодроб - Антинеопластични средства - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Европейски съюз - български - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - Множествена миелома - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Европейски съюз - български - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - Антинеопластични средства - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Европейски съюз - български - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - Имуносупресори - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Европейски съюз - български - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - Меланомът - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Европейски съюз - български - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - Множествена миелома - Антинеопластични средства - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.